Recordati S.a. Chemical and Pharmaceutical Company

Nicox S.a.

First Wave Bio, Inc.

Ems S.a.

Flora Inc.

Other

Pharmacia Ab

Pharmacia & Upjohn Ab

Pharmetrix Corporation

Recordati S.a.

Recordati Ireland Limited

Recordati S.a., Chemical and Pharmaceuticl Company

Ctg Pharma S.r.l.

Giancarlo Santus

Giuseppe Bottoni

Ettore Bilato

Roberto Golzi

Richard W Baker

Piero Del Soldato

Susan Vintilla-Friedman

Gary D Glick

Francesca Benedini

Luigi Franchi

Michael L Francoeur

Luca Donadoni

Ulrike Bremer

Christina Ecclissato

Aeri Kim

Roberto Amazonas

Ennio Ongini

Anna Sparatore

Leticia Khater Covesi

Alberto Tajana

Giovanni Sala

Guiseppe Bottoni

Caterina Lazzarini

Gabriele Lazzarini

This disclosure features chemical entities (e.g., a compound exhibiting activity as a mitochondrial uncoupling agent or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as niclosamide or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof; e.g., a compound, such as a niclosamide analog, or a pharmaceutically acceptable salt and/or hydrate and/or cocrystal thereof) that are useful, e.g., for treating one or more symptoms of a pathology characterized by an abnormal inflammatory response (e.g., inflammatory bowel diseases) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

Methods and compositions for treating conditions associated with an abnormal inflammatory response

Methods and compositions for treating conditions associated with an abnormal inflammatory responses

The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus.

Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus

New compounds able to release COX-2 inhibitors and NO having formula (I):M-T-Y&#x2014;NO&#x2003;&#x2003;(I)for the treatment and/or prophylaxis of inflammatory processes.

Nitrooxyderivatives of cyclooxygenase-2 inhibitors

The present invention refers to a process for preparing a compound of general formula (A), as reported in the description, wherein R is a radical of a drug and R1-R12 are hydrogen or alkyl groups, m, n, o, q, r and s are each independently an integer from 0 to 6, and p is 0 or 1, and X is O, S, SO, SO2, NR13 or PR13 or an aryl, heteroaryl group, said process comprising reacting a compound of formula (B) R&#x2014;COOZ (B) wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1-R12 and m, n, o, p, q, r, s are as defined above and Y is a suitable leaving group.

Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof

An analgesic/anti-inflammatory pharmaceutical dosage form which comprises an effective amount of an active ingredient selected from the group consisting of racemic 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, optically active forms thereof and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient or diluent, said dosage form being an intranasally administrable dosage form.

Therapeutic compositions for intranasal administration which include KETOROLAC

The present invention refers to a process for preparing a compound of general formula (A), as reported in the description, wherein R is a radical of naproxen or bromonaproxen and R&#x2013;Rare hydrogen or alkyl groups, m, n, o, q, r and s are each independently an integer from 0 to 6, and p is 0 or 1, and and X is O, S, SO, SO, NRor PR13 or an aryl, heteroaryl group, said process comprising reacting a compound of formula (B)R&#x2014;COOZ&#x2003;&#x2003;(B)wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1&#x2013;R12 and m, n, o, p, q, r, s are as defined above and Y is a suitable leaving group.

Process for preparing nitrooxyderivatives of naproxen

Probucol derivatives and pharmaceutical compositions containing the same to be employed in treatment or prophylaxis of diseases.

Probucol nitro-derivatives

Therapeutic compositions for intranasal administration which include KETOROLAC&reg;

A pharmaceutical composition suitable for preparing an extemporaneous suspension, that promptly releases active agents or ingredients (drugs) is disclosed. These compositions comprise an active agent in microgranule form. The microgranules containing the active agent are coated with a film coating mixture containing at least one lipid material and an optional hydrophilic additive. The coating envelopes the microgranules but does not impart a controlled release property to the composition, and affords prompt release thereof once ingested.

Prompt-release oral pharmaceutical compositions for extemporaneous suspensions

A method to protect biactive compounds and microorganisms from inactivation in the gastric tract as well as in foods. The method involves preparation and coating of a multiplicity of microgranules containing the compounds or microorganisms. The microgranules are generally smaller than 500 .mu.m and have physical characteristics that permit homogeneous filming as well as ready suspension after coating in common foodstuffs such as milk and milk products and fruit juices.

Stabilized biologically active compounds contained in coated

A method for treating conditions responsive to nicotine therapy, and particularly for smoking cessation therapy and for reducing nicotine craving, is described that utilizes transdermal nicotine delivery for obtaining base-line nicotine plasma levels coupled with transmucosal administration of nicotine to satisfy transient craving.

Method and therapeutic system for smoking cessation

Disclosed are compositions and dosage forms containing moguisteine and having controlled release properties, methods for using such compositions and dosage forms and methods for making them.

Pharmaceutical composition for the controlled release of moguisteine in

Growing community of inventors

Milan, Italy

Giancarlo Santus